A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This is an international, randomized, open-label, Phase 3 study designed to evaluate whether
the potent and selective RET inhibitor, pralsetinib, improves outcomes when compared to a
platinum chemotherapy-based regimen chosen by the Investigator from a list of standard of
care treatments, as measured primarily by progression free survival (PFS), for participants
with RET fusion-positive metastatic NSCLC who have not previously received systemic
anticancer therapy for metastatic disease. Participants who have centrally confirmed
progressive disease on the control arm have the option to crossover to pralsetinib.